|
|
Blood, 20 August 2009, Vol. 114, No. 8, pp. 1457-1458.
Previous Article | Table of Contents | Next Article 

IMMUNOBIOLOGY
Comment on Mumprecht et al, page 1528,Zhang et al, page 1545, andAhmadzadeh et al, page 1537
Blocking PD-1 in cancer immunotherapy
Gianpietro Dotti
BAYLOR COLLEGE OF MEDICINE
Abstract
The PD-1 pathway is emerging as an important tumor-evasion mechanism. In this issue of Blood, 3 independent groups report that PD-1 is highly expressed by tumor-specific cytotoxic T lymphocytes in hematologic and nonhematologic malignancies, and is associated with impaired T-cell function.

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
Related Articles in Blood Online:
-
Programmed death 1 signaling on chronic myeloid leukemia–specific T cells results in T-cell exhaustion and disease progression
- Sabine Mumprecht, Christian Schürch, Juerg Schwaller, Max Solenthaler, and Adrian F. Ochsenbein
Blood 2009 114: 1528-1536.
[Abstract]
[Full Text]
[PDF]
-
Tumor antigen–specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired
- Mojgan Ahmadzadeh, Laura A. Johnson, Bianca Heemskerk, John R. Wunderlich, Mark E. Dudley, Donald E. White, and Steven A. Rosenberg
Blood 2009 114: 1537-1544.
[Abstract]
[Full Text]
[PDF]
-
PD-1/PD-L1 interactions inhibit antitumor immune responses in a murine acute myeloid leukemia model
- Long Zhang, Thomas F. Gajewski, and Justin Kline
Blood 2009 114: 1545-1552.
[Abstract]
[Full Text]
[PDF]
|
|